These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 37127609)
1. Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment. Zhang Y; Wang L; Wang ZD; Zhou Q; Zhou X; Zhou T; Guan YX; Liu X J Nanobiotechnology; 2023 May; 21(1):145. PubMed ID: 37127609 [TBL] [Abstract][Full Text] [Related]
2. Colon-Adhering Delivery System with Inflammation Responsiveness for Localized Therapy of Experimental Colitis. Kumar A; Kanika ; Kumar V; Ahmad A; Mishra RK; Nadeem A; Siddiqui N; Ansari MM; Raza SS; Kondepudi KK; Khan R ACS Biomater Sci Eng; 2023 Aug; 9(8):4781-4793. PubMed ID: 37497615 [TBL] [Abstract][Full Text] [Related]
3. Budesonide-liposomes inclusion complex in thermosensitive gel alleviates DSS-induced ulcerative colitis in mice. Yang D; Zhao Y; Teng L; He J; Zhao J; Gao X; Ma G Drug Dev Ind Pharm; 2023 Apr; 49(4):341-347. PubMed ID: 37272387 [TBL] [Abstract][Full Text] [Related]
4. Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitis. Yang C; Zhang M; Lama S; Wang L; Merlin D J Control Release; 2020 Jul; 323():293-310. PubMed ID: 32335157 [TBL] [Abstract][Full Text] [Related]
5. An efficient enzyme-triggered controlled release system for colon-targeted oral delivery to combat dextran sodium sulfate (DSS)-induced colitis in mice. Li S; Jin M; Wu Y; Jung S; Li D; He N; Lee MS Drug Deliv; 2021 Dec; 28(1):1120-1131. PubMed ID: 34121560 [TBL] [Abstract][Full Text] [Related]
7. Enhanced therapeutic efficacy of a novel colon-specific nanosystem loading emodin on DSS-induced experimental colitis. Wang D; Sun M; Zhang Y; Chen Z; Zang S; Li G; Li G; Clark AR; Huang J; Si L Phytomedicine; 2020 Nov; 78():153293. PubMed ID: 32777486 [TBL] [Abstract][Full Text] [Related]
9. Mucoadhesive Nanoparticles Enhance the Therapeutic Effect of Dexamethasone on Experimental Ulcerative Colitis by the Local Administration as an Enema. Dong K; Deng SJ; He BY; Guo ZY; Guan ZL; Leng X; Ma RR; Wang DY; Xing JF; You CY Drug Des Devel Ther; 2023; 17():191-207. PubMed ID: 36718245 [TBL] [Abstract][Full Text] [Related]
10. Colon-targeted delivery of budesonide using dual pH- and time-dependent polymeric nanoparticles for colitis therapy. Naeem M; Choi M; Cao J; Lee Y; Ikram M; Yoon S; Lee J; Moon HR; Kim MS; Jung Y; Yoo JW Drug Des Devel Ther; 2015; 9():3789-99. PubMed ID: 26229440 [TBL] [Abstract][Full Text] [Related]
11. Oral budesonide for induction of remission in ulcerative colitis. Sherlock ME; MacDonald JK; Griffiths AM; Steinhart AH; Seow CH Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD007698. PubMed ID: 26497719 [TBL] [Abstract][Full Text] [Related]
12. Mucus-Penetrating Alginate-Chitosan Nanoparticles Loaded with Berberine Hydrochloride for Oral Delivery to the Inflammation Site of Ulcerative Colitis. Sun L; Nie X; Lu W; Zhang Q; Fang W; Gao S; Chen S; Hu R AAPS PharmSciTech; 2022 Jun; 23(6):179. PubMed ID: 35761150 [TBL] [Abstract][Full Text] [Related]
13. Oral Delivery of Nanoparticles Loaded With Ginger Active Compound, 6-Shogaol, Attenuates Ulcerative Colitis and Promotes Wound Healing in a Murine Model of Ulcerative Colitis. Zhang M; Xu C; Liu D; Han MK; Wang L; Merlin D J Crohns Colitis; 2018 Jan; 12(2):217-229. PubMed ID: 28961808 [TBL] [Abstract][Full Text] [Related]
14. Lentinan-Based Oral Nanoparticle Loaded Budesonide With Macrophage-Targeting Ability for Treatment of Ulcerative Colitis. Lin M; Dong L; Chen Q; Xu H; Han X; Luo R; Pu X; Qi S; Nie W; Ma M; Wang Y; Gao F; Zhang J Front Bioeng Biotechnol; 2021; 9():702173. PubMed ID: 34513811 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Budesonide-Hydroxypropyl-β-Cyclodextrin Inclusion Complex in Thermoreversible Gels for Ulcerative Colitis. Lázaro CM; de Oliveira CC; Gambero A; Rocha T; Cereda CMS; de Araújo DR; Tofoli GR Dig Dis Sci; 2020 Nov; 65(11):3297-3304. PubMed ID: 31974913 [TBL] [Abstract][Full Text] [Related]
16. pH-triggered surface charge-reversal nanoparticles alleviate experimental murine colitis via selective accumulation in inflamed colon regions. Naeem M; Oshi MA; Kim J; Lee J; Cao J; Nurhasni H; Im E; Jung Y; Yoo JW Nanomedicine; 2018 Apr; 14(3):823-834. PubMed ID: 29353017 [TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of pH-sensitive nanoparticles of budesonide for the treatment of ulcerative colitis. Zhou H; Qian H Drug Des Devel Ther; 2018; 12():2601-2609. PubMed ID: 30174414 [TBL] [Abstract][Full Text] [Related]
18. Mucoadhesive chitosan hydrogels as rectal drug delivery vessels to treat ulcerative colitis. Xu J; Tam M; Samaei S; Lerouge S; Barralet J; Stevenson MM; Cerruti M Acta Biomater; 2017 Jan; 48():247-257. PubMed ID: 27769943 [TBL] [Abstract][Full Text] [Related]
19. Cyclosporine A-loaded colon-targeted oral nanomicelles self-assembly by galactosylated carboxymethyl chitosan for efficient ulcerative colitis therapy. Xiong M; Li Y; He H; Hao S; Fang P; Xu M; Chen Y; Chen Y; Yu S; Hu H Eur J Pharm Biopharm; 2023 Aug; 189():152-164. PubMed ID: 37336365 [TBL] [Abstract][Full Text] [Related]
20. Oral colon-targeted pH-responsive polymeric nanoparticles loading naringin for enhanced ulcerative colitis therapy. Fan S; Zhao Y; Yao Y; Shen X; Chai X; Li J; Pi J; Huang X; Jin H; Zhou Z J Transl Med; 2024 Sep; 22(1):878. PubMed ID: 39350164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]